Everence Capital Management Inc. Decreases Position in Illumina, Inc. (NASDAQ:ILMN)

Everence Capital Management Inc. decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 45.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 4,410 shares of the life sciences company’s stock after selling 3,608 shares during the quarter. Everence Capital Management Inc.’s holdings in Illumina were worth $614,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its stake in Illumina by 312.5% in the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock valued at $702,000 after buying an additional 1,525 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Illumina by 3.1% in the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock valued at $82,853,000 after buying an additional 7,114 shares during the last quarter. Dakota Wealth Management lifted its stake in Illumina by 13.8% in the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock valued at $288,000 after buying an additional 100 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Illumina by 16.9% in the first quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after buying an additional 116 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its stake in Illumina by 10.2% in the first quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after buying an additional 4,548 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a report on Thursday, January 4th. Finally, Barclays boosted their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $167.70.

Insiders Place Their Bets

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.17% of the stock is owned by corporate insiders.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $118.29 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $232.23. The stock’s fifty day simple moving average is $134.31 and its 200-day simple moving average is $128.15.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business posted $0.14 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, research analysts predict that Illumina, Inc. will post 0.91 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.